These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 32328845)

  • 41. Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.
    Sperry BW; Vranian MN; Hachamovitch R; Joshi H; Ikram A; Phelan D; Hanna M
    J Am Heart Assoc; 2016 Mar; 5(3):e002877. PubMed ID: 27013539
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies.
    Koike H; Katsuno M
    Neurol Ther; 2020 Dec; 9(2):317-333. PubMed ID: 32948978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiac Amyloidosis: Presentations, Diagnostic Work-up and Collaborative Approach for Comprehensive Clinical Management.
    Joury A; Gupta T; Krim SR
    Curr Probl Cardiol; 2021 Oct; 46(10):100910. PubMed ID: 34175153
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis.
    Fine NM; Davis MK; Anderson K; Delgado DH; Giraldeau G; Kitchlu A; Massie R; Narayan J; Swiggum E; Venner CP; Ducharme A; Galant NJ; Hahn C; Howlett JG; Mielniczuk L; Parent MC; Reece D; Royal V; Toma M; Virani SA; Zieroth S
    Can J Cardiol; 2020 Mar; 36(3):322-334. PubMed ID: 32145862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Amyloidosis as a Systemic Disease in Context.
    Cuddy SAM; Falk RH
    Can J Cardiol; 2020 Mar; 36(3):396-407. PubMed ID: 32145867
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis)].
    Tereshchenko SN; Zhirov IV; Moiseeva OM; Adasheva TV; Ansheles AA; Barbarash OL; Galyavich AS; Gudkova AI; Zateyshchikov DA; Kostareva AA; Nasonova SN; Nedogoda SV; Pecherina TB; Ryzhkova DV; Sergienko VB
    Ter Arkh; 2022 May; 94(4):584-595. PubMed ID: 36286812
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.
    Maurer MS; Bokhari S; Damy T; Dorbala S; Drachman BM; Fontana M; Grogan M; Kristen AV; Lousada I; Nativi-Nicolau J; Cristina Quarta C; Rapezzi C; Ruberg FL; Witteles R; Merlini G
    Circ Heart Fail; 2019 Sep; 12(9):e006075. PubMed ID: 31480867
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy.
    Vaishnav J; Brown E; Sharma K
    Prog Cardiovasc Dis; 2024; 82():113-124. PubMed ID: 38246305
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy.
    Maurer MS
    Am J Cardiol; 2022 Dec; 185 Suppl 1():S23-S34. PubMed ID: 36371281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Towards a Diagnosis of Cardiac Amyloidosis: Single Center Experience with
    Saleem M; Sadat B; Van Harn M; Ananthasubramaniam K
    Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837580
    [No Abstract]   [Full Text] [Related]  

  • 51. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
    Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
    JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies.
    Warner AL
    Pharmacotherapy; 2021 Dec; 41(12):1081-1091. PubMed ID: 34669976
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Amyloid cardiomyopathy.
    Karafiatova L; Pika T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Jun; 161(2):117-127. PubMed ID: 28145535
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era.
    Martyn T; Saef J; Hussain M; Ives L; Kiang A; Estep JD; Collier P; Starling RC; Cremer PC; Tang WHW; Hanna M; Jaber WA
    J Card Fail; 2022 Oct; 28(10):1509-1518. PubMed ID: 35843490
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Progress in the diagnosis and treatment of cardiac amyloidosis].
    Jurczyszyn A; Engel A; Rajzer M; Czepiel J; Mazurs G
    Przegl Lek; 2014; 71(6):340-5. PubMed ID: 25344976
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiac transthyretin amyloidosis.
    Dungu JN; Anderson LJ; Whelan CJ; Hawkins PN
    Heart; 2012 Nov; 98(21):1546-54. PubMed ID: 22888163
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
    Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
    J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.
    Bistola V; Parissis J; Foukarakis E; Valsamaki PN; Anastasakis A; Koutsis G; Efthimiadis G; Kastritis E
    Heart Fail Rev; 2021 Jul; 26(4):861-879. PubMed ID: 33452596
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
    Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy.
    Takashio S; Morioka M; Ishii M; Morikawa K; Hirakawa K; Hanatani S; Oike F; Usuku H; Kidoh M; Oda S; Yamamoto E; Matsushita K; Ueda M; Tsujita K
    ESC Heart Fail; 2023 Aug; 10(4):2319-2329. PubMed ID: 37073415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.